🇺🇸 FDA
Pipeline program

SYR-472

SYR-472/CCT-101

Phase 3 small_molecule completed

Quick answer

SYR-472 for Type 2 Diabetes Mellitus is a Phase 3 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Type 2 Diabetes Mellitus
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials